Denali Therapeutics (DNLI) Depreciation & Amortization (CF) (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $2.8 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 22.37% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $11.7 million, a 47.06% increase from a year earlier, with the FY2025 full-year figure at $11.2 million, up 43.46% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $2.8 million, down from $2.9 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for DNLI reached as high as $10.0 million in Q1 2023 and fell as low as $1.8 million in Q3 2024.
• Historically, Depreciation & Amortization (CF) has averaged $2.9 million across 5 years, with a median of $2.2 million in 2023.
• Across the five-year window, Depreciation & Amortization (CF) surged 383.26% in 2023 and plunged 78.48% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $4.1 million in 2022, then plunged by 47.01% to $2.2 million in 2023, then dropped by 14.88% to $1.9 million in 2024, then soared by 54.67% to $2.9 million in 2025, then retreated by 0.73% to $2.8 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $2.8 million in Q1 2026, $2.9 million in Q4 2025, and $2.9 million in Q3 2025.